By Jason Derry —

GlaxoSmithKline Plc. has announced a partnership with Genmab A/S relating to a particular
antibody, HuMax-CD20, which is in late-stage clinical development for treating
leukemia, lymphoma, and rheumatoid arthritis.  Under the agreement, GSK will give Genmab an upfront payment of $103
million, and will purchase additional shares in the future, bringing the total
potential value of the deal to $2.1 billion.

The news follows GSK's recently announced acquisition of the antibody therapeutics company, Domantis Ltd.  In that deal,
GSK agreed to buy Domantis for $454 million.

Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.